IOVA

Iovance Biotherapeutics (IOVA) has reported third quarter 2026 results, posting revenue of US$121.47 million and a net loss of US$22.27 million, or a basic and diluted loss of US$0.05 per share.

The latest earnings arrive after a volatile stretch for Iovance Biotherapeutics, with the share price falling 32.9% over the past month but still rising 37.2% over 90 days and delivering a very large year to date share price return of 245.2% and a 1 year total shareholder return of 276.6%. This signals strong momentum over the past year despite a recent pullback as investors weigh rapid progress in lifileucel programs against ongoing losses and clinical risk.

Scan how Iovance Biotherapeutics compares with other fast-moving cancer therapy stocks by reviewing the hand picked 38 healthcare AI stocks that are attracting fresh attention after earnings and trial updates.

Iovance Biotherapeutics now trades well below its recent highs yet still carries a large 1-year gain, so does that pullback reset the odds in favor of buyers or leave little margin for error once valuation is unpacked next?

Most Popular Narrative: 52% Undervalued

Iovance Biotherapeutics last closed at $8.70 while the most followed narrative on the stock pegs fair value at $18.00. That gap frames the entire debate around whether the recent pullback is a reset or just noise after a huge year to date move.

Today, the market capitalization is only around $2 billion, despite Iovance already having an FDA-approved product and guidance for hundreds of millions of dollars in revenue this year. If management executes as planned, I don't think the company should trade like an early-stage biotech anymore.

See why 24 investors see Iovance Biotherapeutics as 52% undervalued.

Result: Fair Value of $18.00 (UNDERVALUED)

Still, two pressure points could quickly challenge the Iovance Biotherapeutics bull case: slower than expected Amtagvi uptake and any setback across lifileucel clinical programs.

Find out about the key risks to this Iovance Biotherapeutics narrative.

Another View: What The Market Is Paying For Iovance Biotherapeutics

The fair value narrative at $18.00 portrays Iovance Biotherapeutics as deeply undervalued, yet the market is already assigning a relatively high price-to-sales (P/S) multiple. At 12.1x sales versus a peer average of 5.7x and a fair ratio of 8.1x, buyers are paying a premium multiple for a stock that some models still characterize as inexpensive. This raises a key question: how comfortable are you paying a premium for a stock that certain frameworks continue to label as cheap?

To see how that premium pricing compares with more detailed ratio analysis, review the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Sentiment around Iovance Biotherapeutics is split between excitement over progress and concern about what could go wrong, so move quickly, review the facts, and decide where you stand by weighing the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Iovance Biotherapeutics?

If you stop with Iovance Biotherapeutics, you risk missing other opportunities that better match your goals, risk limits, and time horizon across sectors and styles.

• Target higher upside potential by scanning the 19 high quality undiscovered gems that combine solid fundamentals with under-the-radar market attention.
• Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (24 results) that can help you focus on companies with stronger financial footing.
• Dial back volatility and sharpen risk control by filtering for a 31 resilient stocks with low risk scores that aims to keep surprises to a minimum.